TCRX TScan Therapeutics
- 8.686
- +0.126+1.47%
TScan Therapeutics News
TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting
WALTHAM, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies
TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares
WALTHAM, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies
Unveiling 4 Analyst Insights On TScan Therapeutics
TScan Therapeutics (NASDAQ:TCRX) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.The table below provides a concise overview of recent
Wedbush: Reiterates the TSCAN Therapeutics (TCRX.US) rating and adjusted from better than market to better than market rating, with a target price of $10.00.
Wedbush: Reiterates the TSCAN Therapeutics (TCRX.US) rating and adjusted from better than market to better than market rating, with a target price of $10.00.
Wedbush Reiterates Outperform on TScan Therapeutics, Maintains $10 Price Target
Wedbush analyst David Nierengarten reiterates TScan Therapeutics with a Outperform and maintains $10 price target.
TScan Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/23/2024 38.31% Wedbush → $10 Reiterates Outperform → Outperform 03/07/2024 24.48% Barclays $7 → $9 Main
TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
WALTHAM, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies
TScan Therapeutics Announces Closing of Upsized Public Offering
WALTHAM, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Zoetis (ZTS) and TScan Therapeutics (TCRX)
TScan Therapeutics Offering Is Expected to Close Around April 19 >TCRX
TScan Therapeutics Offering Is Expected to Close Around April 19 >TCRX
TScan Therapeutics Plans to Use Proceeds for General Corporate Purposes >TCRX
TScan Therapeutics Plans to Use Proceeds for General Corporate Purposes >TCRX
TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering
WALTHAM, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies
TScan Therapeutics Shares Are Trading Lower After the Company Announced That It Commenced a $125 Million Proposed Public Offering. The Company Provided an Update on Its Solid Tumor and Heme Malignancies Clinical Programs.
TScan Therapeutics Shares Are Trading Lower After the Company Announced That It Commenced a $125 Million Proposed Public Offering. The Company Provided an Update on Its Solid Tumor and Heme Malignanci
Press Release: TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering
TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering WALTHAM, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceut
TScan Therapeutics Provides Update On Its Solid Tumor And Heme Malignancies Clinical Programs
Over 40 solid tumor patients have completed all biomarker testing in the screening protocol; ~60% of these patients qualify for at least one TCR-T in the ImmunoBank and ~30% are eligible for multiplex
TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities
Over 40 solid tumor patients have completed all biomarker testing in the screening protocol; ~60% of these patients qualify for at least one TCR-T in the ImmunoBank and ~30% are eligible for multiplex therapy Patients
TScan Therapeutics Appoints Louis As CMO
Press Release: TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer
TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer Dr. Louis brings to TScan extensive experience in cell therapy, medical a
TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference
Hedge Funds Investors Control 50% of TScan Therapeutics, Inc. (NASDAQ:TCRX) and Were Rewarded Last Week After Stock Increased 16%
Key Insights Given the large stake in the stock by institutions, TScan Therapeutics' stock price might be vulnerable to their trading decisions A total of 5 investors have a majority stake in the co
Analysis
Price Target
No Data
